Is Spotting Normal During Menopause? When to See a Doctor

What "Spotting During Menopause" Actually Means Depends on Where You Are in the Transition

The phrase "menopause bleeding" gets used loosely, but clinically your life stage changes everything about what the bleeding means.

Menopause is defined as 12 consecutive months without a menstrual period. Everything before that threshold is perimenopause. Spotting that occurs while you are still in perimenopause sits in a completely different clinical category than spotting that occurs after you have crossed the 12-month line.

Perimenopause (still having some periods)

During perimenopause, ovulation becomes irregular. Your ovaries are producing estrogen in unpredictable surges rather than the steady rhythmic pattern of your reproductive years. Progesterone, which requires ovulation to be made, often fails to rise enough to stabilize the uterine lining. The result is a lining that builds up unevenly and sheds at unexpected times.

Studies published in Menopause journal show that irregular bleeding patterns in the two to three years before the final menstrual period are nearly universal. Cycles can be shorter, longer, heavier, lighter, or simply unpredictable. Light spotting between periods fits this pattern.

That does not mean every perimenopausal bleed is automatically benign. Endometrial hyperplasia, polyps, and fibroids all peak in prevalence during the late reproductive and perimenopausal years. Any bleeding that is significantly heavier than your usual period, occurs after sex, or is accompanied by pelvic pain warrants evaluation regardless of where you are in the transition.

Postmenopause (12 or more months since your last period)

One rule. Full stop. ACOG Practice Bulletin No. 128 and The Menopause Society's clinical practice guidelines are consistent: any bleeding after the 12-month no-period mark must be evaluated to rule out endometrial cancer.

This is not about causing alarm. Most postmenopausal bleeding will not turn out to be cancer. The point is that the 9-10% chance that it is cancer is far too high to ignore.

The Most Common Causes of Postmenopausal and Perimenopausal Bleeding

Most bleeding after menopause comes from benign sources. Knowing the list helps you have a more specific conversation with your clinician.

Endometrial atrophy

Atrophy is the leading cause, accounting for up to 60-80% of postmenopausal bleeding cases. When estrogen drops after menopause, the uterine lining becomes thin and fragile. Even minor trauma, such as a pelvic exam or a vaginal dryness event, can cause a small amount of bleeding from the friable tissue.

Vaginal atrophy (genitourinary syndrome of menopause, GSM)

GSM affects up to 40-50% of postmenopausal women and is frequently underreported. The vulvar, vaginal, and urethral tissues all thin and lose elasticity without estrogen. Light spotting or pink discharge, especially after intercourse, often originates from the vaginal walls rather than the uterus. This is one reason your clinician will examine both the vagina and the cervix before concluding the bleeding source is endometrial.

Endometrial polyps

Polyps are small, finger-like overgrowths of the uterine lining. They are common across the perimenopausal and early postmenopausal years and tend to cause intermenstrual spotting or light postmenopausal bleeding. A Fertility and Sterility analysis found polyps in roughly 24% of women investigated for abnormal uterine bleeding. Most polyps are benign, but a small number harbor atypical cells, which is why removal and histological examination matter.

Submucosal fibroids

Fibroids that protrude into the uterine cavity can cause heavy or irregular bleeding during perimenopause. They typically shrink after menopause as estrogen falls, but fibroids present before menopause may persist for years. If you are on systemic hormone therapy, estrogen can sustain fibroids and occasionally provoke bleeding.

Endometrial hyperplasia

Hyperplasia means overgrowth of the uterine lining. The most concerning form, atypical hyperplasia, carries a roughly 30% risk of progression to endometrial cancer if untreated. It tends to develop when estrogen stimulates the endometrium without adequate progesterone opposition, which can happen during perimenopause or in women on estrogen-only therapy who still have a uterus.

Endometrial cancer

Endometrial cancer is the most common gynecologic cancer in the United States. The American Cancer Society estimates approximately 67,880 new cases in 2024. The median age at diagnosis is 60, squarely in the postmenopausal window. Abnormal uterine bleeding is the presenting symptom in about 90% of cases, which is precisely why postmenopausal bleeding gets taken seriously.

Cervical causes

Cervical polyps, cervicitis, and, less commonly, cervical cancer can produce spotting. A speculum exam will usually distinguish a cervical source from an endometrial one. This is another reason that "wait and see" is not appropriate for postmenopausal bleeding.

Hormone Therapy and Spotting: What Is Expected vs. What Is Not

If you are on hormone replacement therapy (HRT), the bleeding picture changes depending on the regimen you are taking.

Continuous-combined regimens

Continuous-combined HRT (estrogen plus progestogen daily, with no pill-free break) is designed to produce a thin, stable endometrium with no monthly bleed. Breakthrough spotting in the first three to six months is expected and common as the endometrium thins down. The British Menopause Society guidelines note that this early spotting usually resolves by month 6.

Spotting that starts or continues beyond six months on a continuous-combined regimen needs investigation. The differential is the same as for any postmenopausal bleeding: atrophy, polyp, hyperplasia, or malignancy.

Sequential (cyclic) regimens

Sequential regimens give estrogen continuously and progestogen for 10-14 days per cycle, which is intended to produce a predictable withdrawal bleed. On a monthly sequential regimen, you expect a bleed during or after the progestogen phase. Bleeding that occurs at any other time in the cycle, is heavier than usual, or persists beyond the expected window is called unscheduled bleeding and requires evaluation.

Estrogen-only therapy

Estrogen-only HRT is prescribed only for women who have had a hysterectomy. If you still have a uterus and are taking estrogen without progestogen, the endometrium can develop hyperplasia. Any bleeding in this situation is an emergency-level red flag and you should contact your clinician the same day.

Vaginal (local) estrogen

Low-dose vaginal estrogen creams, rings, and tablets release very little estrogen into the bloodstream. A Cochrane review found that local vaginal estrogen does not meaningfully raise endometrial cancer risk in women with an intact uterus when used at recommended doses. Spotting from vaginal estrogen use is usually from the fragile atrophic tissue itself rather than from endometrial stimulation, but it still warrants a clinical check to confirm.

How Your Doctor Will Investigate Abnormal Bleeding

Your evaluation will typically move through a stepwise process.

Step 1: Transvaginal ultrasound (TVUS)

Transvaginal ultrasound measures endometrial thickness. ACOG and the Society of Radiologists in Ultrasound both support an endometrial stripe of <4 mm as a threshold below which endometrial cancer is very unlikely in postmenopausal women not on HRT. A thickness of 4 mm or more, or a thickened lining in a woman on HRT, triggers the next step.

Step 2: Endometrial biopsy

An in-office endometrial biopsy uses a thin plastic catheter (a Pipelle sampler is standard) to aspirate a small sample of the lining. It takes about 60 seconds, causes cramping similar to a period, and has a sensitivity of approximately 91% for endometrial cancer detection. The limitation is that it samples only part of the cavity, so a negative biopsy does not entirely rule out focal lesions like polyps.

Step 3: Hysteroscopy

Hysteroscopy is the gold standard for direct visualization of the uterine cavity. A thin camera is passed through the cervix. Your doctor can see and biopsy polyps, submucosal fibroids, or suspicious areas directly. It may be performed in an office or an operating room depending on your anatomy and local resources.

Saline infusion sonography (SIS)

SIS fills the uterine cavity with saline during ultrasound, making polyps and submucosal fibroids much easier to see than on standard TVUS. It is often ordered when TVUS shows an endometrial stripe that is thickened but the biopsy is negative, or when the ultrasound image is technically limited.

Risk Factors That Raise Your Personal Chance of Endometrial Cancer

Not all postmenopausal bleeding carries equal risk. Several factors shift your probability upward. Knowing yours helps you advocate for timely investigation.

• Obesity: adipose tissue converts androgens to estrogen, providing ongoing endometrial stimulation. Women with a BMI above 30 have a two-to-four-fold increased risk.
• Diabetes mellitus and insulin resistance, including PCOS history.
• Tamoxifen use: tamoxifen acts as an estrogen agonist in the uterus and increases endometrial cancer risk by approximately two-to-threefold.
• Nulliparity (never having given birth).
• Late menopause (after age 55).
• Personal or family history of Lynch syndrome, which carries a lifetime endometrial cancer risk of 25-60%.
• Unopposed estrogen exposure, whether from medication or endogenous sources.

If you have PCOS and are now perimenopausal, your history of chronic anovulation means years of estrogen stimulation without regular progesterone, a pattern that can prime the endometrium for hyperplasia. Tell your clinician explicitly.

When to See a Doctor: A Clear Decision Table

This framework distills the clinical decision logic into a format you can apply directly to your own situation.

| Your situation | Action | |---|---| | Perimenopausal, spotting fits irregular cycle pattern, no other symptoms | Mention at your next routine visit; track cycle in an app | | Perimenopausal, spotting after sex or with no cycle correlation | Call within one week for pelvic exam | | Perimenopausal, bleeding heavier than your heaviest period ever | Call same day or go to urgent care | | Postmenopausal (12+ months no period), any bleeding, any amount | Call within 24-48 hours. Do not wait for your annual exam | | On continuous-combined HRT, spotting in first 6 months | Expected; log it and report if it continues past month 6 | | On continuous-combined HRT, spotting starts after 6 months | Call within one week for evaluation | | On sequential HRT, bleeding outside the expected withdrawal window | Call within one week | | On estrogen-only HRT with intact uterus, any bleeding | Call the same day | | Postmenopausal, bleeding with pelvic pain or pressure | Urgent evaluation, same day |

"Any bleeding after menopause should be evaluated promptly," states The Menopause Society in its clinical practice guidelines. "Although most cases will have a benign explanation, the possibility of endometrial cancer must be excluded."

Life-Stage Breakdown: How the Meaning of Spotting Shifts

Reproductive years and trying to conceive

Spotting before your expected period in the reproductive years is more likely to be implantation bleeding, ovulatory spotting, or cervical sensitivity than anything menopause-related. If you are trying to conceive and have irregular spotting, PCOS is worth screening for, as anovulatory cycles produce irregular bleeding and increase long-term endometrial cancer risk.

Perimenopause (roughly ages 45-55)

This is the life stage where spotting is most common and most often benign. Erratic ovarian function creates the hormonal chaos that produces irregular bleeding. A study in the journal Menopause tracking women through the menopausal transition found that more than 70% experienced at least one episode of irregular or heavy bleeding in the three years before their final period.

The problem is that perimenopause overlaps with the age at which endometrial hyperplasia and early cancer also begin to rise. The ACOG recommendation is that any bleeding that is new, heavier than usual, or occurs after intercourse should be evaluated regardless of perimenopausal status.

Early postmenopause (within 5 years of the final period)

This is the highest-risk window for both benign atrophy and early cancer detection. Women who present with postmenopausal bleeding in their early 50s have a lower absolute risk of cancer than women who present in their late 60s, but the relative change from your personal baseline is still clinically significant.

Late postmenopause (more than 10 years after the final period)

Any bleeding at this stage is more likely to cause alarm in both you and your clinician, and rightly so. The endometrium should be fully quiescent. Even a small amount of spotting decades after menopause has a higher pretest probability of a pathological cause and should be evaluated without delay.

Pregnancy, Lactation, and Contraception: What You Need to Know

Postmenopausal bleeding is by definition a condition of women who are no longer fertile, so pregnancy is not part of the differential after confirmed menopause.

However, two situations require a brief but direct note.

Perimenopause and pregnancy risk

Perimenopause does not mean infertility. Ovulation remains possible during irregular cycles, and ACOG advises that contraception should be used until 12 consecutive months without a period. Spotting during perimenopause could, in a small number of cases, represent implantation bleeding rather than anovulatory irregularity. A home pregnancy test is a reasonable first step before assuming a perimenopausal cause.

HRT and contraception

Standard-dose HRT is not a contraceptive. If you are perimenopausal and start HRT for symptom management while still potentially ovulating, you need a separate contraceptive method. Options that work well in this window include the levonorgestrel intrauterine device (LNG-IUD), which simultaneously protects against pregnancy, provides the progestogen component of HRT, and can reduce heavy perimenopausal bleeding. The progestogen-only pill and barrier methods are also compatible.

Pregnancy on HRT raises serious concerns because systemic estrogen and progestogens during early pregnancy are not tested for safety in controlled trials, and the standard clinical advice is to avoid pregnancy on HRT. If you discover you are pregnant while on HRT, stop the medication and contact your OB immediately.

What You Can Do Right Now

Tracking your bleeding is the single most useful action before any clinical appointment. Use a period or menopause tracking app, or a paper calendar, to note:

• The date bleeding started and stopped.
• How heavy it was (number of pads or tampons, or flow description).
• Any associated symptoms: pelvic pain, discharge odor or color, pain with intercourse, bloating.
• Where you are in your cycle if you are still having periods.
• Any medications, including vaginal estrogen, progesterone, anticoagulants, or tamoxifen.

This information cuts appointment time and allows your clinician to triage correctly. A woman who arrives saying "I had three days of light pink spotting starting on January 15th, 18 months after my last period, with no pain, on no medications" will receive faster and more targeted care than one who says "I had some bleeding a few weeks ago."

The Menopause Society's 2023 position statement on menopausal hormone therapy emphasizes individualized care and shared decision-making. Bringing specific data to that conversation gives you real agency in the process.